Extrait

The primary objective of this study is to evaluate the lung function response following treatment with UMEC 62.5mcg, VI 25mcg, and UMEC/VI 62.5/25mcg administered once-daily via the Novel Dry Powder Inhaler (NDPI) in subjects with COPD.

Critère d'inclusion

• Chronic Obstructive Pulmonary Disease (COPD)